Breaking News

KineMed, Pfizer Extend Diabetes Pact

June 4, 2014

Will continue to explore new approaches in metabolic disease

Pfizer and KineMed Inc. have renewed a non-exclusive research collaboration for the advancement of new approaches in metabolic disease, namely Type II diabetes. The collaboration employs KineMed’s proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.
 
“We are very pleased to announce the extension of this ongoing partnership in an important area of medicine that affects so many Americans. Our translational biomarker platform targets the metabolic processes and pathways that play a pathogenic role in disorders such as diabetes,” said Marc Hellerstein, M.D., Ph.D., president, chief science officer and co-founder at KineMed. “This platform has been useful in accelerating advancement and de-risking compounds in Type II diabetes. We look forward to continuing our work with Pfizer on their compounds in preclinical and clinical trials.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.

  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.